Entity

Time filter

Source Type


Zhang Q.,Qingdao University | Sun L.-J.,Qingdao University | Qi J.,Shanghai JiaoTong University | Yang Z.-G.,Baotou City Central Hospital | Huang T.,Shanghai JiaoTong University
Asian Pacific Journal of Cancer Prevention | Year: 2014

Background: The relationship between obesity and prostate cancer aggressiveness is controversial in recent studies, partly because BMI is the only generally applied marker of obesity. Our study aimed at evaluating the correlation of periprostatic fat (PF) on magnatic resonance imaging (MRI) and adipocytokines with prostate cancer aggressiveness. Patients and method: A total of 184 patients who underwent radical retropubic prostatectomy (RRP) were analyzed retrospectively; different fat measurements on MRI slices and levels of adipocytokines were compared with the clinical and pathologic factors using SSPS ver.13.0. Result: The PF rates showed a statistically significant variation (p=0.019, 0.025) among groups, that is to say, more adipose tissue was distributed in periprostatic areas of high risk patients. Logistic regression analysis adjusted for age revealed a statistically association between the PF, the ratio and the risk of having high-risk disease (p=0.031, 0.024). The levels of IL-6, leptin and c-reactive protein (CRP) significantly increased with the aggressiveness of prostate cancer, and also with PF and its ratio. The strongest correlation was seen between IL-6 and PF (Pearson r coefficient=0.67, P<0.001). No association was observed between adipocytokines and BMI. Conclusion: Periprostatic adiposity not only affects prostate cancer aggressiveness, but also influences the secretion of adipocytokines. IL-6, PF and CRP have promoting effects on progression of prostate cancer. Source


Hu D.,Peking University | Sun Y.,Peking University | Liao Y.,Huazhong University of Science and Technology | Huang J.,Chongqing Medical University | And 2 more authors.
Cardiology (Switzerland) | Year: 2016

Objectives: To assess the blood pressure-lowering efficacy and tolerability of perindopril/amlodipine fixed-dose combinations in Chinese patients with mild-to-moderate essential hypertension not adequately controlled with monotherapy alone. Methods: In 2 separate double-blind studies, patients received a 4-week run-in monotherapy of amlodipine 5 mg or perindopril 4 mg, respectively. Those whose blood pressure was uncontrolled were then randomized to receive the fixed-dose combination of perindopril 5 mg/amlodipine 5 mg (Per/Amlo group) or remain on the monotherapy for 8 weeks. Patients who were uncontrolled at the week 8 (W8) visit were up-titrated for the Per/Amlo combination, or received additional treatment if on monotherapy, for a further 4 weeks. The main efficacy assessment was at 8 weeks. Results: After 8 weeks, systolic blood pressure (SBP; primary criterion) was statistically significantly lower in the Per/Amlo group (vs. Amlo 5 mg, p = 0.0095; vs. Per 4 mg, p < 0.0001). Uncontrolled patients at W8 who received an up-titration of the Per/Amlo combination showed a further SBP reduction. These changes were mirrored by reassuring reductions in diastolic blood pressure. The fixed-dose combinations were well tolerated. Conclusions: Single-pill combinations of perindopril and amlodipine provide hypertensive patients with a convenient and effective method of reducing blood pressure. © 2016 S. Karger AG, Basel. Source


Qiang Z.,Qingdao University | Li-jiang S.,Qingdao University | Jun Q.,Shanghai JiaoTong University | Zhi-gang Y.,Baotou City Central Hospital | And 2 more authors.
Urology Journal | Year: 2014

Purpose: To evaluate the correlation between aggressiveness of prostate cancer (PCa) and obesity measuring the periprostatic fat on magnetic resonance imaging (MRI). Materials and Methods: One hundred eighty-four patients who had undergone radical retropubic prostatectomy (RRP) were analyzed retrospectively. The different fat measurements (periprostatic fat area (PFA), the subcutaneous fat thickness, the anterior and posterior abdominal fat thicknesses and anteroposterior diameter) were performed on the slices of MRI and then compared with the clinical and pathologic characteristics. Results: The PFA and ratio showed a statistically significant differences (P = .019 and P = .025, respectively) among three groups, that is to say, more adipose were distributed in periprostatic area of the high risk patients. Seventy-one patients in clinical stage and 82 patients in Gleason score have the significant differences between pre-operation and post-operation values. In the clinical stage, the PFA and ratio showed a statistically significant differences (P = .014 and P = .037, respectively). The difference group had more periprostatic adipose than the other one (65.26 ± 9.03 vs. 64.44 ± 9.62; 87.52 ± 3.97 vs. 87.30 ± 3.96). Nothing but the "PFA" was significantly different between two groups (P = .017). Logistic regression analysis adjusted for age revealed a statistically significant association between the PFA, the Ratio and the risk of having high-risk disease (P = .031 and P = .024, respectively). Conclusion: The periprostatic adiposity not only affects the PCa aggressiveness, but also has effect in accurate assessment of the tumor stage and grade. We should predict the prognosis of patient with RRP by measuring periprostatic adiposity on pre-operative MRI. Source


Ge M.-L.,General Hospital of Shenyang Military Command | Han Y.-L.,General Hospital of Shenyang Military Command | Huang L.,Chongqing Medical University | Yang L.-X.,Kunming General Hospital of Chengdu Command | And 6 more authors.
Medical Journal of Chinese People's Liberation Army | Year: 2014

Objective To explore the safety and efficacy of rosuvastatin on development of contrast-induced acute kidney injury (CIAKI) due to application of diuretic furosemide after coronary or peripheral vascular intervention during perioperative period in patients with diabetes mellitus (DM) associated with mild-moderate renal insufficiency (MMRI). Methods From Dec. 2008 to Oct. 2011, 2998 patients from 53 centers in China were enrolled in a TRACK-D project. Of them 650 patients with type 2 DM and concomitant MMRI, who received furosemide, were divided into rosuvastatin group (n=321) and control group (n=329), and all underwent coronary/peripheral arterial diagnostic angiography or left heart ventricular angiography. Patients in rosuvastatin group were treated by percutaneous intervention with rosuvastatin 10mg/d every evening for five days (two days before and three days after operation), while those in control group did not receive any statins before operation and within 72 hours after operation. Serum creatinine (Scr) was measured 48 hours before and 48 and 72 hours after exposure to contrast medium, and the incidence of CIAKI was simultaneously observed. Clinical follow-up of cardiovascular events was done at the 30th day after treatment, including heart function aggravation, all-cause mortality, renal dysfunction-induced dialysis and hemofiltration, etc. Results Baseline data were similar between the two groups. Patients randomized to the rosuvastatin group had a significantly lower incidence of CIAKI compared with controls (5.0% vs 9.7%, P=0.024). Clinical follow-up done at the 30th day after treatment indicated that there was no statistical difference in incidence of dialysis, hemofiltration and all-cause mortality between rosuvastatin group and control group. Conclusions Rosuvastatin may significantly reduce the risk of CIAKI in patients with DM associated with MMRI and receive the furosemide during the perioperative period. Source

Discover hidden collaborations